TITLE

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily

AUTHOR(S)
MENEGHINI, LUIGI; ATKIN, STEPHEN L.; GOUGH, STEPHEN C. L.; RAZ, ITAMAR; BLONDE, LAWRENCE; SHESTAKOVA, MARINA; BAIN, STEPHEN; JOHANSEN, THUE; BEGTRUP, KAMILLA; BIRKELAND, KÅRE I.
PUB. DATE
April 2013
SOURCE
Diabetes Care;Apr20123, Vol. 36 Issue 4, p858
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin. RESEARCH DESIGN AND METHODS--This 26-week, open-label, treat-to-target trial en- rolled adults (≥18 years) with type 2 diabetes who were either insulin naïve and receiving oral anti- diabetic drugs (OADs) (HbA1c =7-11%) or previously on basal insulin ± OAD(s) (HbA1c = 7-10%). Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8-40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg OD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlar OD; n = 230). The primary outcomewas noninferiority of IDegODFlex to IGlar OD in HbA1c reduction after 26weeks. RESULTS--After 26 weeks, IDeg OD Flex, IDeg OD, and IGlar OD improved HbA1c by 1.28, 1.07, and 1.26% points, respectively (estimated treatment difference [IDeg OD Flex 2 IGlar OD]: 0.04% points [-0.12 to 0.20], confirming noninferiority). No statistically significant differences in overall or nocturnal hypoglycemia were found between IDeg OD Flex and IGlar OD. Comparable glycemic control and rates of hypoglycemia were seen with IDeg OD Flex and IDeg OD. Adverse event profiles were similar across groups. CONCLUSIONS--The use of extreme dosing intervals of 8-40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety.
ACCESSION #
86262066

 

Related Articles

  • Pharmacokinetics of a Fixed-Dose Combination of Mitiglinide and Metformin versus Concurrent Administration of Individual Formulations in Healthy Subjects. Jin Ah Jung; Jung-Ryul Kim; Suk-Ran Kim; Tae-Eun Kim; Soo-Youn Lee; Jae-Wook Ko; Wooseong Huh // Clinical Drug Investigation;2012, Vol. 32 Issue 12, p799 

    Background In the treatment of diabetes mellitus, combined drugs with different mechanisms of action can be effective when adequate glycaemic control is difficult with monotherapy. A fixed-dose combination (FDC) tablet of mitiglinide and metformin has been developed as a second-line treatment...

  • Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus. Kolodka, Tadeusz; Charles, Matthew L.; Raghavan, Arvind; Radichev, Ilian A.; Amatya, Christina; Ellefson, Jacob; Savinov, Alexei Y.; Nag, Abhijeet; Williams, Mark S.; Robbins, Mark S. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Modulation of the kallikrein-kinin system (KKS) has been shown to have beneficial effects on glucose homeostasis and several other physiological responses relevant to the progression of type 2 diabetes mellitus (T2D). The importance of bradykinin and its receptors in mediating these responses is...

  • A Feasibility Study of a 3-Day Basal-Bolus Insulin Delivery Device in Individuals With Type 2 Diabetes. Mader, Julia K.; Lilly, Leslie C.; Aberer, Felix; Korsatko, Stefan; Strock, Ellie; Mazze, Roger S.; Damsbo, Peter; Pieber, Thomas R. // Diabetes Care;May2014, Vol. 37 Issue 5, p1476 

    OBJECTIVE This study tested the feasibility of transition from multiple daily injections (MDI) to a 3-day, basal-bolus insulin delivery device (PaQ) for type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twenty MDI-treated individuals with T2D with HbA1c ≤9% (75 mmol/mol) were enrolled in...

  • Diabetes.  // Geriatrics;Jul99, Vol. 54 Issue 7, p12 

    Reports on the approval of rosiglitazone maleate (Avandia) for the treatment of type 2 diabetes as monotherapy or in combination with metformin by the United States Food and Drug Administration. How rosiglitazone works in the body; Effects of the drug on blood sugar levels; Recommended starting...

  • Insulin Therapy for Type 2 Diabetes. Swinnen, Sanne G.; Hoekstra, Joost B.; Devries, J. Hans // Diabetes Care;Nov2009 Supplement, Vol. 32, pS253 

    The article presents an overview of various insulin preparations and an outline of the advantages and disadvantages of different regimens commonly used for the initiation and intensification of insulin therapy in type 2 diabetes patients. Among the available options for additional insulin...

  • BYDUREON.  // Monthly Prescribing Reference;Mar2012, Vol. 28 Issue 3, pA-7 

    The article offers information on the drug Bydureon for type II diabetes from Amylin Pharmaceuticals Inc. and Alkermes Inc. It further informs about the prescribing information of this drug and states that subcutaneous drug injection should be given to adults immediately after mixing two...

  • The glycemic go-getters. Chase, James // Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p42 

    The article focuses on the achievements of Victoza PCP which has posted billions of dollars in global sales for 2011. It highlights the approval of a non-insulin injectable glucagon-like peptide 1 (GLP-1) given by the U.S. Food and Drug Administration (FDA) indicated for patients with Type 2...

  • Bromocriptine in Diabetes Mellitus - A Review. Pandita, Aakriti; Azher, Idrees // Asian Student Medical Journal;2013, Vol. 13 Issue 6, p1 

    The article presents information on the approval of the drug QR-bromocriptine by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus. It mentions that the drug is an antidiabetic that helps in reducing plasma glucose, triglycerides and cardiovascular events....

  • Why, when and how insulin therapy is being started for patients with type 2 diabetes treated with oral medications: an observation study. Dudzińska, Marta; Tarach, Jerzy S.; Malicka, Joanna; Kurowska, Maria; Kowalczyk, Mariusz; Nowakowski, Andrzej // Experimental & Clinical Diabetology / Diabetologia Doswiadczalna;2011, Vol. 11 Issue 2, p45 

    Background. Secondary failure of oral medications is observed annually in 10% of diabetic patients. Introducing insulin therapy is the next stage in the model of progressive treatment of type 2 diabetes. The aim of the study was to evaluate the indications for insulin therapy and to determine...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics